One‐year clinical outcome in an unselected patient population treated with the Genous™ endothelial progenitor cell capturing stent

Objective : We assessed the 1‐year clinical outcome in a large cohort of unselected patients treated with an endothelial progenitor cell (EPC) capturing coronary stent. Background : The novel EPC capturing stent is coated with CD34+ antibodies that bind circulating EPCs to the stent surface, thereby accelerating endothelialization of the stent struts; it is hypothesized that this may prevent restenosis and stent thrombosis. Methods : A total of 405 unselected patients were treated percutaneously with the EPC capturing stent. The majority of patients had complex lesions with an estimated high risk of restenosis. Results : The primary endpoint defined as the composite of cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR) at 1‐year was 13.3%, mainly attributable to TLR which was 10.9%. The occurrence of definite and probable ST was low, 0.5 and 0.7%, respectively. Based on the risk of restenosis, in patients with an estimated high risk of restenosis ( n = 249), the composite primary endpoint was 16.1% versus 9.0% in patients with an estimated low risk ( n = 155). Moreover, the 1 year clinical outcomes in diabetic patient compared well with the nondiabetic patients. Conclusion : In this single‐center study, the 1‐year clinical follow‐up in a “real‐world” population treated with the EPC capturing stent showed good results. Currently, large randomized studies are conducted to evaluate the long‐term safety and efficacy of this stent. © 2011 Wiley‐Liss, Inc.